| |
| |
|
| Insider
Information: |
Torley Helen |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
683,004 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$31,666,361 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
683,004 |
|
|
| Total
Value |
$31,666,361 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -28.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Chief Commercial ... |
2013-10-01 |
0 |
2011-08-29 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
676,744 |
2014-09-16 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Quest Diagnostics Inc |
DGX |
Director |
2021-05-25 |
6,260 |
2018-05-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-08-12 |
4 |
AS |
$126.89 |
$1,181,478 |
D/D |
(9,311) |
46,585 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$3,571,875 |
D/D |
(28,575) |
0 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$917,000 |
D/D |
(7,336) |
28,575 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-09-03 |
4 |
D |
$123.62 |
$259,478 |
D/D |
(2,099) |
35,911 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-05-13 |
4 |
AS |
$97.26 |
$809,610 |
D/D |
(8,250) |
47,646 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2012-10-04 |
4 |
AS |
$86.51 |
$200,184 |
D/D |
(2,314) |
43,259 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-04-01 |
4 |
AS |
$86.14 |
$40,141 |
D/D |
(466) |
47,646 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-02-04 |
4 |
AS |
$78.61 |
$648,533 |
D/D |
(8,250) |
39,512 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2012-11-12 |
4 |
AS |
$75.22 |
$902,414 |
D/D |
(11,997) |
39,512 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Opertaing Officer |
• – – |
2012-07-25 |
4 |
AS |
$73.97 |
$336,498 |
D/D |
(4,549) |
60,701 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2012-09-04 |
4 |
AS |
$72.78 |
$136,681 |
D/D |
(1,878) |
56,823 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Commercial Officer |
• – – |
2012-08-06 |
4 |
S |
$71.89 |
$143,780 |
D/D |
(2,000) |
58,701 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-12-13 |
4 |
AS |
$58.64 |
$586,627 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-12-14 |
4 |
AS |
$58.30 |
$582,980 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-12-15 |
4 |
AS |
$57.29 |
$573,694 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-11-15 |
4 |
AS |
$54.11 |
$541,146 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-11-16 |
4 |
AS |
$53.90 |
$538,990 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-01-19 |
4 |
AS |
$52.41 |
$524,140 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2022-11-17 |
4 |
AS |
$52.15 |
$521,490 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-02-08 |
4 |
AS |
$51.36 |
$513,570 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-02-07 |
4 |
AS |
$51.26 |
$512,580 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-01-18 |
4 |
AS |
$51.05 |
$510,470 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-02-10 |
4 |
D |
$50.60 |
$784,755 |
D/D |
(15,509) |
486,295 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-01-17 |
4 |
AS |
$50.40 |
$504,539 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-02-09 |
4 |
AS |
$50.40 |
$504,000 |
D/D |
(10,000) |
587,177 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
